Cancer BiologybioRxiv
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
G. Sartori, C. Tarantelli, F. Spriano…·F. Bertoni
This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.
DOI 10.1111/bjh.19218